Synthesis of Cis-fused pyran indolocarbazole derivatives that inhibit FLT3 kinase and the DNA damage kinase, checkpoint Kinase 1

Anti-Cancer Agents in Medicinal Chemistry

Volumn 12, Issue 3, 2012, Pages 194-201

  Perron Sierra, Françoise M ^a   Kucharkzyk, Nathalie ^a   Boucley, Céline ^a   Guyard Daumas, Christel ^a   Sciberras, Sophie ^a   Fouache, Christine ^a   Plantier, Sabine ^a   Studeny, Aurélie ^a   Bossard, Céline ^a   Casara, Patrick J ^a   Golsteyn, Roy M ^b  

^a INSTITUT DE RECHERCHES SERVIER   (France)

^b UNIVERSITY OF LETHBRIDGE   (Canada)

Author keywords

Checkpoint adaptation; Checkpoint kinase 1; Chk1; FLT3; Genotoxic agents; HT29 cells; Indolocarbazoles; Protein kinases; Stereospecific synthesis

Indexed keywords

6,7,12,13 TETRAHYDRO 12,13 (1',2' PYRANYL) 5H INDOLO[2,3 A]PYRROLO[3,4 B]CARBAZOLE 5,7(6H) DIONE; 6,7,12,13 TETRAHYDRO 12,13 [(5' HYDROXYMETHYLPYRANYL)] 5H INDOLO[2,3 A]PYRROLO[3,4 B]CARBAZOLE 5,7(6H) DIONE; 6,7,12,13 TETRAHYDRO 12,13 [1',2' (5' AMINOMETHYLPYRANYL)] 5H INDOLO[2,3 A]PYRROLO[3,4 B]CARBAZOLE 5,7(6H) DIONE; 6,7,12,13 TETRAHYDRO 12,13 [1',2' (5' BENZYLOXYMETHYLPYRANYL)] 5H INDOLO[2,3 A]PYRROLO[3,4 B]CARBAZOLE 5,7 (6H) DIONE; 6,7,12,13 TETRAHYDRO 12,13 [1',2' (5' DIMETHYLAMINOMETHYLPYRANYL)] 5H INDOLO[2,3 A]PYRROLO[3,4 B]CARBAZOLE 5,7 (6H) DIONE, TRIFLUOROACETATE; 6,7,12,13 TETRAHYDRO 12,13 [1',2' (5' ETHYLAMINOMETHYLPYRANYL)] 5H INDOLO[2,3 A]PYRROLO[3,4 B]CARBAZOLE 5,7 (6H) DIONE, TRIFLUOROACETATE; 6,7,12,13 TETRAHYDRO 12,13 [1',2' (5' HYDROXYMETHYLPYRANYL)] 5H INDOLO[2,3 A]PYRROLO[3,4 B]CARBAZOLE 5,7 (6H) DIONE; 6,7,12,13 TETRAHYDRO 12,13 [1',2' (5' METHYLAMINOMETHYLPYRANYL)] 5H INDOLO[2,3 A]PYRROLO[3,4 B]CARBAZOLE 5,7(6H) DIONE, TRIFLUOROACETATE; 6,7,12,13 TETRAHYDRO 12,13 [1',2' (5' PROPYLAMINOMETHYLPYRANYL)] 5H INDOLO[2,3 A]PYRROLO[3,4 B]CARBAZOLE 5,7 (6H) DIONE, TRIFLUOROACETATE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CARBAZOLE DERIVATIVE; CD135 ANTIGEN; CHECKPOINT KINASE 1; ENZYME INHIBITOR; PYRAN DERIVATIVE; S 27888; TOXIC SUBSTANCE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOCHEMISTRY; CANCER CELL CULTURE; CELL ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; STRUCTURE ACTIVITY RELATION;

CARBAZOLES; DNA DAMAGE; FMS-LIKE TYROSINE KINASE 3; HT29 CELLS; HUMANS; INDOLES; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PYRAN COPOLYMER;

EID: 84857713437     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Busby, E.C.; Leistritz, D.F.; Abraham, R.T.; Karnitz, L.M.; Sarkaria, J.N. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res., 2000, 60, 2108-2112.
2. Prudhomme, M. Novel Checkpoint 1 inhibitors. Recent Pat. Anti-Cancer Drug Disc., 2006, 1, 55-68.
3. Bailly, C.; Colson, P.; Houssier, C.; Rodrigues-Pereira, E.; Prudhomme, M.; Waring, M.J. Recognition of specific sequences in DNA by a topoisomerase I inhibitor derived from the antitumor drug rebeccamycin. Mole. Pharm., 1998, 53, 77-87.
4. Marminon, C.; Anizon, F.; Moreau, P.; Pfeiffer, B.; Pierre, A.; Golsteyn, R.M.; Peixoto, P.; Hildebrand, M.P.; David-Cordonnier, M.H.; Lozach, O.; Meijer, L.; Prudhomme, M. Rebeccamycin derivatives as dual DNA-damaging agents and potent checkpoint kinase 1 inhibitors. Mol. Pharmacol., 2008, 74, 1620-1629.
5. Liu, Q.; Guntuku, S.; Cui, X.; Matsuoka, S.; Cortez, D.; Tamai, K.; Luo, G.; Carattini-Rivera, S.; DeMayo, F.; Bradley, A.; Donehower, L.A.; Elledge, S.J. Chk1 is an essential kinase that is regulated by Atr and required for the G2/M DNA damage checkpoint. Genes Dev., 2000, 14, 1448-1459.
6. Mailand, N.; Falck, J.; Lukas, C.; Syljuasen, R.G.; Welcker, M.; Bartek, J.; Lukas, J. Rapid destruction of human Cdc25A in response to DNA damage. Science, 2000, 288, 1425-1429.
7. Jones, C.B.; Clements, M.K.; Wasi, S.; Daoud, S.S. Enhancement of camptothecin-induced cytotoxicity with UCN-01 in breast cancer cells: abrogation of S/G2 arrest. Cancer Chemother. Pharmacol., 2000, 45, 252-258.
8. Cahuzac, N.; Studény, A.; Marshall, K.; Versteege, I.; Wetenhall, K.; Pfeiffer, B.; Léonce, S.; Hickman, J.A.; Pierré, A.; Golsteyn, R.M. An unusual DNA binding compound, S23906, induces mitotic catastrophe in cultured human cells. Cancer Lett., 2010, 289, 178-187.
9. Zhao, H.; Piwnica-Worms, H. ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol. Cell. Biol., 2001, 21, 4129-4139.
10. Henon, H.; Conchon, E.; Hugon, B.; Messaoudi, S.; Golsteyn, R.M.; Prudhomme, M. Pyrrolocarbazoles as checkpoint 1 kinase inhibitors. Anticancer Agents Med. Chem., 2008, 8, 577-597.
11. Sanz, M.; Burnett, A.; Lo-Coco, F.; Lowenberg, B. FLT3 inhibition as a targeted therapy for acute myeloid leukemia. Curr. Opin. Oncol., 2009, 21, 594-600.
12. Marzabadi, C.H.; Spilling, C.D.; Tyler, L.M. The chemistry of glucal halohydrins: The effect of the halide on epoxide formation Tetrahedron, 1994, 50, 6783-6796.
13. Faul, M.M.; Sullivan, K.A.; Grutsch, J.L.; Winneroski, L.L.; Shih, C.; Sanchez-Martinez, C.; Cooper, J.T. Synthesis of indolo [2,3-a]carbazole glycoside analogs of rebeccamycin: inhibitors of cyclin D1-CDK4 Tetrahedron Letts, 2004, 45, 1095-1098.
14. Ferry, G.; Studény, A.; Bossard, C.; Kubara, P.M.; Zeyer, D.; Renaud, J.-P.; Casara, P.; de Nanteuil, G.; Wierzbicki, M.; Pfeiffer, M.; Prudhomme, M.; Leonce, S.; Pierré, A.; Boutin, J.A.; Golsteyn, R.M. Characterization of novel Checkpoint kinase 1 inhibitors by in vitro assays and in human cancer cells treated with topoisomerase inhibitors. Life Sci., 2011, 89, 259-268.
15. Parmentier, J.G.; Portevin, B.; Golsteyn, R.M.; Pierre, A.; Hickman, J.; Gloanec, P.; De Nanteuil, G. Synthesis and CHK1 inhibitory potency of hymenialdisine analogues. Bioorg. Med. Chem. Lett., 2009, 19, 841-844.
16. Henon, H.; Anizon, F.; Golsteyn, R.M.; Leonce, S.; Hofmann, R.; Pfeiffer, B.; Prudhomme, M. Synthesis and biological evaluation of new dipyrrolo [3,4-a:3,4-c]carbazole-1,3,4,6-tetraones, substituted with various saturated and unsaturated side chains via palladium catalyzed cross-coupling reactions. Bioorg. Med. Chem., 2006, 14, 3825-3834.
17. Tanizawa, A.; Fujimori, A.; Fujimori, Y.; Pommier, Y. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J. Natl. Cancer Inst., 1994, 86, 836-842.
18. Chou, T.C.; Talalay, P. A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems. J. Biol. Chem., 1977, 252, 6438-6442.
19. Tse, A.N.; Schwartz, G.K. Potentiation of cytotoxicity of topoisomerase I poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe. Cancer Res., 2004, 64, 6635-6644.
20. Facompré, M.; Baldeyrou, B.; Bailly, C.; Anizon, F.; Marminon, C.; Prudhomme, M.; Colson, P.; Houssier, C. DNA targeting of two new antitumour rebeccamycin derivatives. Eur. J. Med. Chem., 2002, 37, 925-932.
21. Zhao, B.; Bower, M.J.; McDevitt, P.J.; Zhao, H.; Davis, S.T.; Johanson, K.O.; Green, S.M.; Concha, N.O.; Zhou, B.B. Structural basis for Chk1 inhibition by UCN-01. J. Biol. Chem., 2002, 277, 46609-46615.
22. Stirewalt, D.L.; Radich, J.P. The role of FLT3 in haematopoietic malignancies. Nat. Rev. Cancer, 2003, 3, 650-665.
23. Kelly, L.M.; Yu, J.C.; Boulton, C.L.; Apatira, M.; Li, J.; Sullivan, C.M.; Williams, I.; Amaral, S.M.; Curley, D.P.; Duclos, N.; Neuberg, D.; Scarborough, R.M.; Pandey, A.S.H.; Abe, K.; Lokker, N.A.; Gilliland, D.G.; Giese, N.A. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell, 2002, 1, 421-432.
24. Tao, Z.-F.; Lin, N.H. Chk1 inhibitors for novel cancer treatment. Anticancer Agents Med. Chem., 2006, 6, 377-388.
25. Anizon, F.; Moreau, P.; Sancelme, M.; Voldoire, A.; Prudhomme, M.; Ollier, M.; Severe, D.; Riou, J.F.; Bailly, C.; Fabbro, D.; Meyer, T.; Aubertin, A.M. Syntheses, biochemical and biological evaluation of staurosporine analogues from the microbial metabolite rebeccamycin. Bioorg. Med. Chem., 1998, 6, 1597-1604.
26. Faul, M.M.; Winneroski, L.L.; Krumrich, C.A. Synthesis of Rebeccamycin and 11-Dechlororebeccamycin. J. Org. Chem., 1999, 64, 2456-2470.
27. Gallant, M.; Link, J.T.; Danishefsky, S. A stereoselective synthesis of indole-.beta.-N-glycosides: an application to the synthesis of rebeccamycin. J. Organ. Chem., 1993, 58, 343-349.
28. Kaneko, T.; Wong, H.; Okamoto, K.T.; Clardy, J. Two synthetic approaches to rebeccamycin Tetrahed. Letts., 1985, 26, 4015-4018
29. Kuntz, K.; O'Connell, M.J. The G(2) DNA damage checkpoint: could this ancient regulator be the Achilles heel of cancer? Cancer Biol. Ther., 2009, 8, 1433-1439.
30. Kindler, T.; Lipka, D.B.; Fischer, T. FLT3 as a therapeutic target in AML: still challenging after all these years. Blood, 2010, 116, 5089-5102.
31. Yee, K.W.; O'Farrell, A.M.; Smolich, B.D.; Cherrington, J.M.; McMahon, G.; Wait, C.L.; McGreevey, L.S.; Griffith, D.J.; Heinrich, M.C. SU5416 and SU5614 inhibit kinase activity of wildtype and mutant FLT3 receptor tyrosine kinase. Blood, 2002, 100, 2941-2949.
32. Petrelli, A.; Valabrega, G. Multitarget drugs: the present and the future of cancer therapy. Expert Opin. Pharmacother., 2009, 10, 589-600.
33. Yao, Q.; Weigel, B.; Kersey, J. Synergism between etoposide and 17-AAG in leukemia cells: critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51. Clin. Cancer Res., 2007, 13, 1591-1600.
34. Nakano, H.; Omura, S. Chemical biology of natural indolocarbazole products: 30 years since the discovery of staurosporine. J. Antibiot., 2009, 62, 17-26.